Medicilon Honors Revolution Medicines with Client Partnership Award

Medicilon Inc. awarded Revolution Medicines with the "Excellence in Client Partnership Award" during a visit to its Nanhui R&D Center. Dr. Yang Liu and Dr. Kristof Pota from Revolution Medicines engaged in project discussions with Medicilon's leadership team. This award highlights the clinical value of Revolution Medicines' pan-KRAS drug development, demonstrating a successful bilateral collaboration.

The partnership, active for over three years, has focused on tackling R&D challenges and delivering high-quality molecules. Revolution Medicines recently achieved U.S. FDA approval for Daraxonrasib, a treatment for metastatic pancreatic cancer, marking a significant milestone in cancer therapy.

Discussions during the visit focused on enhancing R&D collaboration, cross-regional data transfer, and improving cross-border project efficiency. Medicilon showcased its R&D labs and infrastructure, accredited by NMPA, FDA GLP, and other standards, emphasizing its capacity to support innovative drug programs.